A 3-part illustration depicting a radioactivity measurement device and radioactive-labeled package, a patient receiving radioligand therapy, and a male health care professional disposing of waste in a radioactivelabeled waste bin.

Providing and administering RLT

This section of the Novartis RLT Institute is designed to help health care professionals (HCPs) understand radiation safety procedures for providing and administering radioligand therapies (RLTs) manufactured by Novartis. It is based on guidelines from regulatory agencies, including the Nuclear Regulatory Commission (NRC), the Department of Transportation (DOT), and the United States Pharmacopeia (USP). Topics include safe transport, administration, and postadministration protocols to prepare the patient and room for subsequent use.

Postadministration

Reportable events

Misadministration of RLTs may require that the appropriate regulatory bodies be notified (ie, NRC and/or state regulators for Agreement States). Reportable events include, but are not limited to¹:

Dose delivered differs from the prescribed dose by 20% or more
Use of the wrong RLT
Use of the wrong route of administration
Administration to the wrong patient

Clinic considerations

Assessment

Up Next